NovoCure Balance Sheet Health
Financial Health criteria checks 4/6
NovoCure has a total shareholder equity of $362.5M and total debt of $568.8M, which brings its debt-to-equity ratio to 156.9%. Its total assets and total liabilities are $1.1B and $783.6M respectively.
Key information
156.9%
Debt to equity ratio
US$568.82m
Debt
| Interest coverage ratio | n/a |
| Cash | US$910.62m |
| Equity | US$362.50m |
| Total liabilities | US$783.63m |
| Total assets | US$1.15b |
Recent financial health updates
NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
Apr 08
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Nov 16Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?
Aug 13Is NovoCure (NASDAQ:NVCR) A Risky Investment?
May 15Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Jan 16Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Sep 09Recent updates
NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
Apr 08NovoCure: Sell The METIS-Inspired Rally
Mar 28Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio
Mar 03NovoCure: Stay Cautious Amid Positive Signs
Jan 19Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Nov 16Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?
Aug 13Is NovoCure (NASDAQ:NVCR) A Risky Investment?
May 15A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)
Apr 24Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching
Feb 10Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Jan 16NovoCure: See Past Market Myopia And Buy The Dip
Sep 27Novocure creates new CNS focused franchise to renew growth in brain cancer business
Sep 21Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Sep 09NovoCure: Does The Reward Outweigh The Risk? I Believe So
Sep 09NovoCure Q2 2022 Earnings Preview
Jul 27Is NovoCure (NASDAQ:NVCR) Using Too Much Debt?
May 28NovoCure: A Stalwart With More Upsides
May 09NovoCure: Overview Of The GBM Business
Feb 28Health Check: How Prudently Does NovoCure (NASDAQ:NVCR) Use Debt?
Feb 14NovoCure: Time For A Cure
Jan 01NovoCure: Threshold Of Greatness
Nov 30Financial Position Analysis
Short Term Liabilities: NVCR's short term assets ($1.0B) exceed its short term liabilities ($179.1M).
Long Term Liabilities: NVCR's short term assets ($1.0B) exceed its long term liabilities ($604.5M).
Debt to Equity History and Analysis
Debt Level: NVCR has more cash than its total debt.
Reducing Debt: NVCR's debt to equity ratio has increased from 133.1% to 156.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NVCR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NVCR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.